145 related articles for article (PubMed ID: 19618074)
1. Risk factors for ML Flow seropositivity in leprosy patients.
Grossi MA; Leboeuf MA; Andrade AR; Bührer-Sékula S; Antunes CM
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():39-44. PubMed ID: 19618074
[TBL] [Abstract][Full Text] [Related]
2. The influence of ML Flow test in leprosy classification.
Grossi MA; Leboeuf MA; Andrade AR; Lyon S; Antunes CM; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():34-8. PubMed ID: 19618073
[TBL] [Abstract][Full Text] [Related]
3. The use of ML Flow test in school children diagnosed with leprosy in the district of Paracatu, Minas Gerais.
Ferreira IN; Ferreira IL; Evangelista Mdo S; Alvarez RR
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():77-80. PubMed ID: 19618081
[TBL] [Abstract][Full Text] [Related]
4. Association between anti-pGL-I IgM and clinical and demographic parameters in leprosy.
Schuring RP; Moet FJ; Pahan D; Richardus JH; Oskam L
Lepr Rev; 2006 Dec; 77(4):343-55. PubMed ID: 17343221
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with anti-phenolic glycolipid-I seropositivity among the household contacts of leprosy cases.
Carvalho AP; da Conceição Oliveira Coelho Fabri A; Corrêa Oliveira R; Lana FC
BMC Infect Dis; 2015 May; 15():219. PubMed ID: 26024906
[TBL] [Abstract][Full Text] [Related]
6. Association of the ML Flow serologic test to slit skin smear.
Lyon S; Castorina da Silva R; Lyon AC; Grossi MA; Lyon SH; Azevedo Mde L; Bührer-Sékula S; Rocha MO
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():23-6. PubMed ID: 19618071
[TBL] [Abstract][Full Text] [Related]
7. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy.
Brito Mde F; Ximenes RA; Gallo ME; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():67-72. PubMed ID: 19618079
[TBL] [Abstract][Full Text] [Related]
8. Leprosy serology (ML Flow test) in borderline leprosy patients classified as paucibacillary by counting cutaneous lesions: an useful tool.
Barreto JA; Nogueira ME; Diorio SM; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():45-7. PubMed ID: 19618075
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of ML Flow test in leprosy contacts from State of Minas Gerais, Brazil.
Andrade AR; Grossi MA; Bührer-Sékula S; Antunes CM
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():56-9. PubMed ID: 19618077
[TBL] [Abstract][Full Text] [Related]
10. The relation between seroprevalence of antibodies against phenolic glycolipid-I among school children and leprosy endemicity in Brazil.
Bührer-Sékula S; van Beers S; Oskam L; Lecco R; Madeira ES; Dutra MA; Luis MC; Faber WR; Klatser PR
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():81-8. PubMed ID: 19618082
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the agreement between clinical and laboratorial exams in the diagnosis of leprosy.
Teixeira AC; Cruvinel DL; Roma FR; Luppino LF; Resende LH; Sousa Td; Bührer-Sékula S; Goulart IM
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():48-55. PubMed ID: 19618076
[TBL] [Abstract][Full Text] [Related]
12. The ML flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients.
Bührer-Sékula S; Visschedijk J; Grossi MA; Dhakal KP; Namadi AU; Klatser PR; Oskam L
Lepr Rev; 2007 Mar; 78(1):70-9. PubMed ID: 17518099
[TBL] [Abstract][Full Text] [Related]
13. The result patterns of ML Flow and ELISA (PGL-I) serologic tests in leprosy-endemic and non-endemic areas.
Silva RC; Lyon S; Araos R; Lyon AC; Grossi MA; Lyon SH; Penido RA; Bührer-Sékula S; Antunes CM
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():19-22. PubMed ID: 19618070
[TBL] [Abstract][Full Text] [Related]
14. Seroepidemiological study of leprosy in a highly endemic population of south India based on an ELISA using synthetic PGL-I.
Krishnamurthy P; Rao PS; Reddy BN; Subramanian M; Dhandayudapani S; Bhatia V; Neelan PN; Dutta A
Int J Lepr Other Mycobact Dis; 1991 Sep; 59(3):426-31. PubMed ID: 1890366
[TBL] [Abstract][Full Text] [Related]
15. A comparison of ML Flow serology and slit skin smears to assess the bacterial load in newly diagnosed leprosy patients in Brazil.
Lyon S; Lyon AC; Da Silva RC; Grossi MA; Lyon SH; Bührer-Sékula S; Rocha MO
Lepr Rev; 2008 Jun; 79(2):162-70. PubMed ID: 18711938
[TBL] [Abstract][Full Text] [Related]
16. Can anti-PGL-1 and anti-NDO-LID-1 antibody titers be used to predict the risk of reactions in leprosy patients?
Devides AC; Rosa PS; de Faria Fernandes Belone A; Coelho NMB; Ura S; Silva EA
Diagn Microbiol Infect Dis; 2018 Jul; 91(3):260-265. PubMed ID: 29669693
[TBL] [Abstract][Full Text] [Related]
17. Leprosy serology using PGL-I: a systematic review.
Moura RS; Calado KL; Oliveira ML; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():11-8. PubMed ID: 19618069
[TBL] [Abstract][Full Text] [Related]
18. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment.
Eichelmann K; González González SE; Salas-Alanis JC; Ocampo-Candiani J
Actas Dermosifiliogr; 2013 Sep; 104(7):554-63. PubMed ID: 23870850
[TBL] [Abstract][Full Text] [Related]
19. IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy.
Ulrich M; Smith PG; Sampson C; Zuniga M; Centeno M; Garcia V; Manrique X; Salgado A; Convit J
Int J Lepr Other Mycobact Dis; 1991 Sep; 59(3):405-15. PubMed ID: 1890364
[TBL] [Abstract][Full Text] [Related]
20. Correlation between ELISA and ML Flow assays applied to 60 Brazilian patients affected by leprosy.
Da Silva RC; Lyon S; Lyon AC; Grossi MA; Lyon SH; Bührer-Sékula S; Antunes CM
Trans R Soc Trop Med Hyg; 2010 Aug; 104(8):546-50. PubMed ID: 20621218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
